Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8329657 | 0.81 | CYP2A6 (0.44) | EGFRCYP2A6HSD17B10ALDH5A1ABAT | |
| SCHEMBL2154504 | 0.80 | KMT2A (0.47) | CYP2A6KMT2ALMNAMAPTL3MBTL1 | |
| SCHEMBL6592666 | 0.79 | KMT2A (0.58) | KMT2AALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL8763328 | 0.78 | KMT2A (0.42) | KMT2AALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL4137976 | 0.77 | CYP2A6 (0.41) | EGFRCYP2A6HSD17B10ALDH5A1ABAT | |
| SCHEMBL350919 | 0.77 | ALDH1A1 (0.50) | KMT2AALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL12944865 | 0.77 | KDM4E (0.39) | EGFRKMT2AKDM4E | |
| SCHEMBL2561914 | 0.75 | ENPP2 (0.49) | CYP2A6KMT2AALDH1A1KDM4ERAB9A | |
| SCHEMBL17087247 | 0.75 | HIF1A (0.42) | EGFRCYP2A6HSD17B10ALDH5A1ABAT | |
| SCHEMBL3976211 | 0.75 | CYP2A6 (0.52) | CYP2A6HSD17B10ALDH5A1ABATKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622954-B2 | Estrogen receptor ligands, compositions and methods related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210196667-A1 | ESTROGEN RECEPTOR LIGANDS, COMPOSITIONS AND METHODS RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-01 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018024602-A1 | 2,7-DIAZASPIRO[4.4]NONANES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-02-08 | — | — | WO | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
| US-5374641-A | Thromboxane synthetase inhibitors, prostaglandin H2 antagonist , anticoagulants and antiallergens | TERUMO KABUSHIKI KAISHA (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0501876-A1 | N-(3-pyridylalkyl)sulfonamide derivative and pharmaceutical preparation containing thereof | TERUMO KABUSHIKI KAISHA (JP) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | EGFR 3984/4885CYP2A6 1592/4885HSD17B10 3910/4885 |
| US-20210196667-A1 | ESTROGEN RECEPTOR LIGANDS, COMPOSITIONS AND METHODS RELATED THERETO | ESR2, ESRRG, ESR1 | EGFR 78/4885CYP2A6 1651/4885HSD17B10 1010/4885 |
| US-11622954-B2 | Estrogen receptor ligands, compositions and methods related thereto | ESR2, ESRRG, ESR1 | EGFR 78/4885CYP2A6 1651/4885HSD17B10 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.